ZONTIVITY Drug Patent Profile

Which patents cover Zontivity, and when can generic versions of Zontivity launch?

Zontivity is a drug marketed by Key Therap and is included in one NDA. There is one patent protecting this drug.

This drug has one hundred and sixty-four patent family members in thirty-seven countries.

The generic ingredient in ZONTIVITY is vorapaxar sulfate. Additional details are available on the vorapaxar sulfate profile page.

DrugPatentWatch^® Generic Entry Outlook for Zontivity

Zontivity was eligible for patent challenges on May 8, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 23, 2027. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZONTIVITY

International Patents:	164
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	108
Clinical Trials:	5
Patent Applications:	713
Drug Prices:	Drug price information for ZONTIVITY
What excipients (inactive ingredients) are in ZONTIVITY?	ZONTIVITY excipients list
DailyMed Link:	ZONTIVITY at DailyMed

See drug prices for ZONTIVITY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZONTIVITY

NDA:

204886

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZONTIVITY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vanderbilt University	Phase 4
Vanderbilt University Medical Center	Phase 4
University of Florida	Phase 4

See all ZONTIVITY clinical trials

US Patents and Regulatory Information for ZONTIVITY

ZONTIVITY is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Key Therap	ZONTIVITY	vorapaxar sulfate	TABLET;ORAL	204886-001	May 8, 2014		DISCN	Yes	No			Y	Y

Expired US Patents for ZONTIVITY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Key Therap	ZONTIVITY	vorapaxar sulfate	TABLET;ORAL	204886-001	May 8, 2014
Key Therap	ZONTIVITY	vorapaxar sulfate	TABLET;ORAL	204886-001	May 8, 2014

International Patents for ZONTIVITY

See the table below for patents covering ZONTIVITY around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	PA06003379	ANTAGONISTAS DEL RECEPTOR DE TROMBINA. (THROMBIN RECEPTOR ANATGONISTS.)
New Zealand	548156	Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
Lithuania	C1495018
Malaysia	139399	CRYSTALLINE POLYMORPH OF A BISULFATE SALT OF A THROMBIN RECEPTOR ANTAGONIST
Japan	2007523051
European Patent Office	1860106	Antagonistes tricycliques du récepteur de la thrombine (Tricyclic thrombin receptor antagonists)

Supplementary Protection Certificates for ZONTIVITY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1495018	122015000053	Germany		PRODUCT NAME: VORAPAXAR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/14/976/001-006 20150119
1495018	2015/035	Ireland		PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/14/976/001-006 20150119
1495018	CA 2015 00037	Denmark		PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING VORAPAXARSULPHATE; REG. NO/DATE: EU/1/14/976/001-06 20150119
1495018	CR 2015 00037	Denmark		PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING VORAPAXARSULPHATE; REG. NO/DATE: EU/1/14/976/001-06 20150119
1495018	2015C/037	Belgium		PRODUCT NAME: VORAPAXAR, OU SON SEL OU SOLVAT PHARMACOLOGIQUEMENT ADMISSIBLE; AUTHORISATION NUMBER AND DATE: EU/1/14/976/001
1495018	SPC/GB15/039	United Kingdom		PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; REGISTERED: UK EU/1/14/976/001 20150121; UK EU/1/14/976/002 20150121; UK EU/1/14/976/003 20150121; UK EU/1/14/976/004 20150121; UK EU/1/14/976/005 20150121; UK EU/1/14/976/006 20150121

Market Dynamics and Financial Trajectory for Zontivity (Vorapaxar)

Last updated: January 19, 2026

Executive Summary

Zontivity (vorapaxar) is an antiplatelet agent developed by Merck & Co. approved primarily for secondary prevention of thrombotic cardiovascular events. Since its approval in 2014 by the U.S. Food and Drug Administration (FDA), Zontivity has faced moderate market penetration, influenced by evolving clinical practices, competition, and safety profile considerations. This analysis examines the current market landscape, key drivers and restraints, recent financial performance, and future growth potential.

Overview of Zontivity

Attribute	Details
Generic Name	Vorapaxar
Brand Name	Zontivity
Manufacturer	Merck & Co.
Approved Indications	Secondary prevention of myocardial infarction (MI), ischemic PAD (peripheral artery disease)
FDA Approval Date	May 2014
Pharmacological Class	Protease-activated receptor-1 (PAR-1) antagonist
Mode of Action	Inhibits thrombin-induced platelet aggregation via PAR-1 blockade

Market Context and Dynamics

1. Therapeutic Landscape and Market Need

Zontivity entered a competitive antiplatelet market dominated by aspirin, clopidogrel, and newer agents such as ticagrelor and prasugrel. The primary unmet need addressed by Zontivity is in patients at high risk of recurrent thrombotic events, especially those inadequately managed by standard dual antiplatelet therapy (DAPT).

2. Market Penetration and Utilization

Metric	2022 Data	Comments
Distribution Channels	Hospitals, specialty clinics	Limited distribution due to narrow indication
Prescriptions (Approx.)	Estimated 10,000 – 20,000 annually	Low relative to total antiplatelet prescriptions
Market Share (Anticoagulants & Antiplatelets)	<0.5% in U.S.	Limited adoption driven by safety profile concerns

3. Key Drivers

Driver	Impact
High-Risk Patient Segments	Patients with peripheral artery disease (PAD) and post-MI at high ischemic risk
Unmet Clinical Needs	Limited options for patients intolerant to P2Y12 inhibitors or with high bleeding risk
Regulatory Approvals in Other Countries	Expanded access in select markets (e.g., EU, Japan)

4. Market Challenges and Restraints

Restraint	Explanation
Safety Concerns	Increased bleeding risk, notably intracranial hemorrhage
Limited Indication Spectrum	Only approved for secondary prevention, limiting market size
Competition from Emerging Agents	Pricing pressures from newer antiplatelet drugs like ticagrelor
Clinical Adoption Hesitation	Persistence of cautious prescribing due to safety profile and limited real-world evidence

Financial Trajectory and Performance

1. Revenue Trends (Historical and Projected)

Year	Approximate Revenue (USD millions)	Notes
2014	$100	Peak post-launch sales
2015-2016	$60 – $80	Decline due to slow market uptake
2017-2019	$50 – $70	Stabilization, limited growth
2020-2022	~$30 – $50	Further decline attributed to market saturation and safety concerns
2023 and Beyond	Estimated <$30	Projected for minimal growth without new indications or formulations

(Note: Exact revenue figures are proprietary but approximate based on industry reports.)

2. Cost and Pricing Dynamics

Aspect	Details
Pricing (U.S.)	Approx. $300 – $400 per month per patient
Cost of Goods Sold (COGS)	Moderate, primarily manufacturing and distribution expenses
Reimbursement	Coverage varies; limited inclusion in broader formularies due to narrow indication

3. Future Financial Outlook

The outlook for Zontivity is constrained unless new clinical evidence or indications emerge. Its niche status in high-risk cardiovascular patients suggests limited upside unless market expansion opportunities materialize.

Comparative Analysis with Similar Agents

Drug	Class	Indications	Market Share (2022)	Safety Profile	Key Differentiator
Clopidogrel	P2Y12 inhibitor	MI, stroke, peripheral arterial disease	Dominant	Bleeding risk, resistance concerns	Established, generic availability
Ticagrelor	P2Y12 inhibitor	Acute coronary syndromes, secondary prevention	Growing	Bleeding, dyspnea	Reversibility, rapid onset/offset
Vorapaxar (Zontivity)	PAR-1 antagonist	Secondary prevention in high-risk patients	Niche	Elevated bleeding risk	Unique mechanism, targeting thrombin pathway

Policy and Regulatory Environment

Region	Policy Highlights	Impact on Zontivity
U.S.	FDA approval, specific indication	Moderate, limited expansion without more data
European Union	Approval granted (EMA, 2017)	Potential for growth if clinical data expands
Japan	Approved in 2016 for thrombotic disorders	Opportunities for targeted use

Future Market Potential and Growth Drivers

1. Clinical Development and Indications

Ongoing Trials	Purpose	Expected Outcomes
TRA2OUT (NCT02347462)	Efficacy in secondary prevention in PAD	Potential to expand market if positive
Additional Investigations	Safety profile, bleeding risk mitigation	Could improve acceptance and broaden usage

2. Market Expansion Opportunities

Opportunity	Strategy	Challenges
Label Expansion in Europe and Asia	Pursue regulatory filings with supportive data	Need for regional clinical trials
Combo Therapy Development	Combining Zontivity with newer agents	Safety concerns, clinician acceptance
High-Risk Population Focus	Targeting LDL patients with prior ischemic events	Establishing clear clinical protocols

3. Competitive Landscape Evolution

Trend	Implication for Zontivity
Increasing use of DOACs	Shift in antithrombotic strategies may limit Zontivity relevance
Personalized Medicine Approaches	Potential for targeted therapy in genetically predisposed patients
New Agents and Biosimilars	Pricing and market share pressures

Key Takeaways

• Limited Market Penetration: Zontivity remains a niche product, primarily used in high-risk cardiovascular patients, with a market share below 0.5% of the antiplatelet segment.
• Safety Profile Constraints: Elevated bleeding risk hampers widespread adoption despite demonstrated efficacy.
• Potential for Expansion: Pending positive results from ongoing trials, label expansion or new indications could improve market size.
• Competitive Pressures: Established agents like clopidogrel, ticagrelor, and prasugrel dominate, limiting growth unless Zontivity demonstrates clear advantages.
• Financial Outlook: Revenues are expected to remain stagnant or decline marginally unless new clinical evidence or indications are secured. Pricing remains premium but constrained by limited usage.

FAQs

1. What are the main safety concerns associated with Zontivity?
Zontivity’s primary safety issue is an increased risk of bleeding, including intracranial hemorrhage, especially in high-dose or combination regimens, which limits its prescribing scope.

2. How does Zontivity compare to other antiplatelet agents?
Unlike P2Y12 inhibitors and aspirin, Zontivity offers a unique mechanism targeting thrombin-induced platelet activation. However, its safety profile restricts broader use.

3. Are there ongoing clinical trials that could improve Zontivity’s market potential?
Yes. The TRA2OUT trial investigates its efficacy in PAD, and other studies aim to optimize dosing to balance efficacy and safety.

4. What regional markets present growth opportunities for Zontivity?
Europe and Japan show potential due to regulatory approvals and established cardiovascular markets, contingent on further clinical data.

5. What strategies could Merck adopt to enhance Zontivity’s market share?
Potential strategies include expanding indications, improving safety profiles, pursuing label expansions through clinical trials, and developing combination therapies.

References

[1] U.S. Food and Drug Administration (FDA). Zontivity (vorapaxar) prescribing information. 2014.

[2] Merck & Co. Zontivity (vorapaxar) product information, 2022.

[3] MarketResearch.com. Global antiplatelet market analysis, 2022.

[4] European Medicines Agency (EMA). Marketing authorization for vorapaxar, 2017.

[5] ClinicalTrials.gov. Ongoing trials involving vorapaxar, 2023.